Precision BioSciences Inc
NASDAQ:DTIL

Watchlist Manager
Precision BioSciences Inc Logo
Precision BioSciences Inc
NASDAQ:DTIL
Watchlist
Price: 6.86 USD -5.25% Market Closed
Market Cap: 52.6m USD
Have any thoughts about
Precision BioSciences Inc?
Write Note

Precision BioSciences Inc
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Precision BioSciences Inc
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Precision BioSciences Inc
NASDAQ:DTIL
Common Shares Outstanding
$7.5m
CAGR 3-Years
55%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Common Shares Outstanding
$1.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Common Shares Outstanding
$1.2B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Common Shares Outstanding
$537.5m
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Common Shares Outstanding
$257.7m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Common Shares Outstanding
$110.1m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
No Stocks Found

Precision BioSciences Inc
Glance View

Market Cap
51.3m USD
Industry
Biotechnology

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 198 full-time employees. The company went IPO on 2019-03-28. The company is developing ex vivo allogeneic CAR T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform. The firm's ARCUS platform is designed to deliver therapeutic-grade genome editing. Its ARCUS genome editing technology is for deoxyribonucleic acid (DNA) genome insertion, deletion and repair. Its ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae Chlamydomonas reinhardtii to make specific cuts and DNA insertions in cellular DNA. Its Ex vivo Allogeneic CAR T Immunotherapy pipeline offers programs, including PBCAR0191, PBCAR19B, PBCAR269A and CD19 Combination with Foralumab. Its in-vivo Gene Correction pipeline offers three preclinical programs, including PBGENE-PCSK9, PBGENE-PH1 and PBGENE-HBV. Its subsidiaries include Precision PlantSciences, Inc. and Precision BioSciences UK Limited.

DTIL Intrinsic Value
12.31 USD
Undervaluation 44%
Intrinsic Value
Price

See Also

What is Precision BioSciences Inc's Common Shares Outstanding?
Common Shares Outstanding
7.5m USD

Based on the financial report for Sep 30, 2024, Precision BioSciences Inc's Common Shares Outstanding amounts to 7.5m USD.

What is Precision BioSciences Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
35%

Over the last year, the Common Shares Outstanding growth was 94%. The average annual Common Shares Outstanding growth rates for Precision BioSciences Inc have been 55% over the past three years , 35% over the past five years .

Back to Top